

Evaluation of two rapid lateral flow tests and two surrogate ELISAs for the detection of SARS-CoV-2 specific neutralizing antibodies

Philipp Girl^{1,2*}, Katrin Zwirgmaier^{1,2*}, Heiner von Buttlar^{1,2}, Roman Wölfel^{1,2}, Katharina Müller^{1,2}

¹Bundeswehr Institute of Microbiology, Neuherbergstraße 11, 80937 Munich, Germany

²German Centre for Infection Research (DZIF), partner site Munich, Germany.

*The authors contributed equally

Corresponding author: PhilippGirl@bundeswehr.org

Abstract

Introduction: As vaccination against SARS-CoV-2 progresses rapidly around the world, reliable detection of SARS-CoV-2 specific neutralizing antibodies (NAb) has become an indispensable component of serological diagnostics. We evaluated the performance of four commercially available tests, i.e. two lateral flow assays (Coris BioConcept COVID-19 Sero NP/RBD and Concile InfectCheck COVID-19 NAb) and two surrogate ELISA (sELISA) tests (EUROIMMUN SARS-CoV-2 NeutralISA and AdipoGen SARS-CoV-2 Neutralizing Antibodies Detection Kit) in comparison with an in-house SARS-CoV-2 micro neutralization test as reference.

Methods: A total of 334 sera were tested, including 30 samples collected prior to the emergence of SARS-CoV-2, 128 sera from convalescent patients as well as 176 sera from partially or fully vaccinated individuals.

Results: The overall sensitivity of LFAs differed and was 71.6% for the Coris and 98.4% for the Concile. In contrast, overall sensitivity of the NeutralISA was 86% and 98% for the AdipoGen. All test showed the highest sensitivity when testing samples from fully vaccinated individuals with both sELISA achieving 100% sensitivity. Overall specificity was 89.3% for the Coris and only 58.3% for the Concile. Similarly significant differences were observed for both sELISA, with an overall specificity of 82.1% for the NeutralISA and only 54.8% for the AdipoGen. All tests showed a 100% specificity when testing negative control samples while specificities were lowest when testing samples from only partially vaccinated individuals.

Conclusion: Our findings support the potential use of the Concile LFA and both sELISA for the detection of NABs against SARS-CoV-2, especially to determine NAb levels after complete vaccination.

Keywords: COVID-19, SARS-CoV-2, neutralizing antibodies, ELISA, lateral flow assay

Conflict of interest: The authors declare that there is no conflict of interest.

Funding statement: This study was funded by the Medical Biodefense Research Program of the Bundeswehr Medical Service.

Introduction

Serological testing has become a useful tool in the fight against the SARS-CoV-2 pandemic. Among others, it can be used to estimate the prevalence and incidence in a given population [1,2]. Countless serological tests have been commercialized by now, including enzyme-linked immunosorbent assays (ELISAs) as well as point-of-care lateral flow assays (LFAs). These tests typically measure SARS-CoV-2 specific antibodies, often even specific immunoglobulin subclasses (i.e. IgG, IgM or IgA). In this context, neutralizing antibodies (NAbs) have emerged as a strong correlate of protection and are therefore being used to evaluate vaccine efficacy or select appropriate convalescent plasma for therapeutic use [3]. However, they represent only a small subset of the total polyclonal immune response.

The main target of NAbs is the spike (S) protein, more precisely the Receptor Binding Domain (RBD) located at the outer end of the S1 subunit. This is responsible for the binding of SARS-CoV-2 to the Angiotensin-Converting Enzyme-2 (ACE2) receptor on the surface of the cell [4]. Thus, it is not surprising that a recent study found that at least 90% of SARS-CoV-2 NAbs are RBD specific. However, not all RBD-specific antibodies are able to neutralize the virus [5]. Thus, to efficiently assess the level of protection from (re-)infection rather than just demonstrate a prior encounter with SARS-CoV-2, serological tests need to be able to differentiate between neutralizing and non-neutralizing antibodies.

Plaque-reduction (PRNT) and neutralization (NT) tests are the current gold standards for the detection and quantification of NAbs [6]. However, these assays are labor-intensive and require appropriate biocontainment laboratories (BSL-3) because they depend on working with infectious virus. The number of laboratories that can perform these tests is therefore limited [7]. Previously described pseudo virus-based techniques can be performed under BSL-2 conditions, but also require the cultivation of reporter virus and therefore do not provide a significant time advantage [8,9]. A potential alternative to classic neutralization assays comes in the form of surrogate ELISAs (sELISA). They rely on the ability of NAbs to bind RBD and prevent its interaction with ACE2. sELISA use recombinant proteins and colorimetric analysis to determine this competitive inhibition and several versions of this type of assay have been commercialized [10]. In addition, LFAs have been developed and are particularly appealing as point-of-care (POC) tests due to their rapid turnaround times and simplicity of use [11]. In

contrast to sELISA, they are designed as sandwich assays to detect RBD-specific antibodies with neutralizing capability.

In this study, we investigated four commercially available tests for the detection of SARS-CoV-2 specific NABs: two surrogate ELISAs (Euroimmun SARS-CoV-2 NeutralISA and AdipoGen SARS-CoV-2 Neutralizing Antibodies Detection Kit) and two LFAs (Coris BioConcept COVID-19 Sero NP/RBD and Concile InfectCheck COVID-19 NAb). We tested all four assays side-by-side and in direct comparison with our in-house NT to determine both sensitivity and specificity and to test their potential as an alternative to conventional NT.

Material and Methods

Serum samples

We tested a total of 334 human serum samples. Of these samples, 304 had previously tested positive for SARS-CoV-2 antibodies in a commercial IgG ELISA (Euroimmun, Lübeck, Germany), which was used as a pre-screening assay (Table S1)). Of these, 128 samples came from PCR-confirmed convalescent patients of which 78 were registered convalescent plasma donors; all samples were taken at least six weeks after full recovery. Another 177 samples came from vaccinated individuals and were taken at least four weeks after vaccination. Of these, 40 individuals had received their primary vaccination with Vaxzevria (AstraZeneca) while the other 136 individuals were fully vaccinated either with Comirnaty (Pfizer/BioNTech), Spikevax (Moderna) or a heterologous vaccination with Vaxzevria (AstraZeneca) as prime and Spikevax as boost. The remaining 30 serum samples were collected before the occurrence of SARS-CoV-2 (mid to late 2018) and served as negative control samples. An overview of all samples is given in Figure 1.

Ethical statement: The study was carried out in-line with “The Code of Ethics of the World Medical Association (Declaration of Helsinki)”. The use of serum samples complied with the guidelines of the Central Ethics Committee of the German Medical Association (Dtsch Arztebl 2003; 100(23): A-1632). In accordance with these guidelines, the anonymized use of residual material from the samples sent to our laboratory for diagnostic purposes is permissible, provided that the patients have not decided against this procedure. Samples from patients who had decided against this procedure were excluded from the analyses.

Neutralization test (NT)

SARS-CoV-2 NAb titers were determined as previously described [12]. Briefly, serum samples (duplicates) were serially diluted in 96-well tissue culture plates starting at 5 to a maximum of 640 along with positive and negative control samples. SARS-CoV-2 stocks (50 TCID₅₀/50µl, MUC-IMB-1 [EPI_ISL_406862]) were prepared on Vero E6 cells and aliquots were stored at -80°C until further use. Virus was pre-incubated (1h, 37°C) with diluted serum samples before Vero E6 cells (1x10⁴ cells/50µl) were added to each well. After 72 hours (37°C), supernatants were discarded and wells were fixed (13% formalin/PBS) and stained with crystal violet (0.1%). The NAb titer corresponded to the reciprocal of the highest sample dilution showing complete inhibition of cytopathic effects. A virus re-titration was performed in triplicates on every plate and exact titers were determined by retrograde calculation.




Figure 1: Overview of sample origin A total of 334 samples were tested. A commercial IgG ELISA (Euroimmun, Lübeck, Germany) was used for pre-screening. All but 30 samples were positive for SARS-CoV-2 IgG antibodies, of which 128 came from patients who had recently recovered from confirmed COVID-19 and 177 were from vaccinated individuals (collected at least three weeks after vaccination). In addition, 30 samples collected in mid to late 2018 served as negative control samples.

Surrogate ELISAs

Two commercially available sELISA kits were tested in this study: The SARS-CoV-2 NeutralISA (Euroimmun, Lübeck, Germany) and the SARS-CoV-2 Neutralizing Antibodies Detection Kit (AdipoGen Life Sciences, Liestal, Switzerland). Both tests function very similarly and are based on the competitive inhibition of the RBD-ACE2 interaction by NABs. AdipoGen provides RBD-coated plates and uses HRP-conjugated ACE2 while Euroimmun uses the total S1 subunit of the S protein for coating and biotin-conjugated ACE2 (Figure 2 A&B). Both test were carried out strictly according the manufacturer's instructions.

The NeutralISA is the only test studied here that classifies results not only as positive or negative, but also as "indeterminate". We followed a conservative approach for the evaluation of the test results and evaluated indeterminate results as negative.




Figure 2: Schematic Illustration of the different designs of the four tests evaluated as disclosed by the manufacturers

Lateral flow assays

Two commercially available LFAs were evaluated in this study: COVID-19 Sero NP/RBD test (Coris BioConcept, Belgium) and the InfectCheck COVID-19 NAb test (Concile GmbH Germany/Affimedix Inc. USA). Both are sandwich immuno assays. The Concile LFA uses colloidal gold particles that are conjugated with the RBD to bind to the NAb and mouse-anti-human IgG immobilized on the test line of the membrane to capture the NAb bound to the

gold. (Figure 2C). The Coris BioConcept detects not only RBD antibodies, but also antibodies against the nucleocapsid protein. Since all vaccines currently in use elicit an immune response against the spike protein, while an infection elicits an immune response against all components of SARS-CoV-2, the LFA can differentiate between immune response acquired through vaccination or infection. The test uses N protein and RBD immobilized on separate test lines to capture the respective antibodies (Figure 2D). The other half of the immune sandwich consists of gold particles that are presumably (not detailed in the instructions for use) conjugated with anti-human IgG.

Both tests were carried out according to manufacturer's instructions. Briefly, for the COVID-19 Sero NP/RBD test 30µl serum were applied to the test cassette followed by 4 drops of buffer 10 seconds later. Results were read out after 15 min and photographically documented within 15-20 min. Line intensities were evaluated visually by comparison to a visual analog colour scale (Figure S2). Intensities on the scale range from 0-9 and were recorded separately for test line and control line. Values of 2 or greater were scored as positive. A value of 1 corresponds to a very faint line that could not be reliably identified by different test operators and was therefore scored as negative. For the InfectCheck COVID-19 Nab test 5 µl serum were mixed with 5 drops of buffer and applied to the test cassette. Results were read out visually after 15 minutes as described above and photographically documented within 15-20 min. In addition to that, results were also measured with the concile α1 reader.




Figure S2: In-house visual analog scale for standardized assessment of line intensity of colloidal gold lateral flow assays.

Results

Detection of SARS-CoV-2 specific neutralizing antibodies by NT

Initially, all 334 samples were examined in our in-house NT. Serum samples with a titer equal to or greater than 5 were considered positive. In total, 84 samples tested negative for neutralizing antibodies while the remaining 250 tested positive. Among the samples that tested negative were all 30 negative control samples, 14 samples from convalescent patients and all serum sample from individuals who had only received their primary vaccination. Positive samples consisted of 114 sera from convalescent patients and 136 sera from fully vaccinated individuals. In summary, 100% of sera from fully vaccinated individuals and 89% of convalescent sera tested positive for NABs while 100% of both negative control samples and samples from individuals that received their primary vaccination tested negative. An overview of the distribution of NT results by sample origin is given in Table 1.

Sample origin	number of samples	NT positive	NT negative
convalescent patients	128	114	14
partially vaccinated individuals	40	0	40
fully vaccinated individuals	136	136	0
negative control samples	30	0	30
Total	334	250	84

Table 1: Distribution of the results (positive/negative) from the in-house NT in relation to sample origin All (100%) of the NT positive samples came from fully vaccinated individuals and convalescent patients while the majority (83.3%) of NT negative samples came from only partially vaccinated individuals and negative control samples.

Influence of natural infection and immunization on neutralizing antibody titers

The titer values determined by NT significantly differ between convalescent patients and fully vaccinated individuals. While the median titer of sera from convalescent patients was 37, it

was 3.5 times higher (129) for sera from vaccinated individuals. Figure 3 shows the distribution of titer values among fully vaccinated individuals (left) and recovered patients (right).

Among serum samples from vaccinated individuals, one-third (28%) have low titers of 5 to 10. At the same time, 34% show a slightly higher titer of either 20 or 40 while the remaining samples (38%) have a titer equal to or greater than 80. In more detail, 17% of vaccinated individuals have a titer between 80 and 160 while another 21% reached the highest titer values of 320 or more. In contrast, only 4% of convalescent patients have titer values that high while another 8% have a titer between 80 and 160. Instead, the majority (45%) of convalescent patients have a titer of either 5 or 10 and another one third (32%) have a titer of 20 to 40. In addition, no NAb at all could be detected in 11% of sera.




Fig 3: Titer values among fully vaccinated (left) differ from titer values of recovered patients (right) In general, titers were higher among fully vaccinated individuals with 38% having a titer of at least 80 or higher including 21% with a titer of equal to or greater than 320. In contrast, 45% of convalescent patients had a titer of 5 or 10 while in 11% no NAb could be detected at all.

Sensitivity and Specificity of commercial Immunoassays

In addition, all 334 samples were subsequently also analyzed using two sELISA (AdipoGen and NeutralISA) as well as two LFAs (Coris and Concile). Sensitivity and specificity were determined in direct comparison to the results of the NT. A detailed overview of the results of the individual immunoassays, including subgroup specific results, is shown in table 2.

NT			sELISA		LFA	
			AdipoGen	NeutralISA	Coris	Concile
Sensitivity positive (titer ≥ 5)	all samples	<i>n</i> =250	98% (245/250)	86% (215/250)	71.6% (179/250)	98.4% (246/250)
	convalescent	<i>n</i> =114	95.6% (109/114)	69.3% (79/114)	65.8% (75/114)	97.4% (111/114)
	fully vaccinated	<i>n</i> =136	100% (136/136)	100% (136/136)	76.5% (104/136)	99.3% (135/136)
Specificity negative (titer < 5)	all samples	<i>n</i> =84	54.8% (46/84)	82.1% (69/84)	89.3% (75/84)	58.3% (49/84)
	convalescent	<i>n</i> =14	42.9% (6/14)	100% (14/14)	85.7% (12/14)	42.9% (6/14)
	partially vaccinated	<i>n</i> =40	25% (10/40)	62.5% (25/40)	82.5% (33/40)	32.5% (13/40)
	control samples	<i>n</i> =30	100% (30/30)	100% (30/30)	100% (30/30)	100% (30/30)

Table 2: Detailed overview of overall sensitivity and specificity of the four evaluated commercial immunoassays in comparison to NT results. Sensitivities and specificities

With regard to the entirety of samples examined all but five NT-positive samples were identified by the AdipoGen sELISA, resulting in the overall highest sensitivity of 98%. In comparison, of the 250 NT-positive samples, 215 samples tested positive in the NeutralISA giving an overall sensitivity of 86%. However, of the 84 NT-negative samples, 38 tested positive in the AdipoGen whereas the NeutralISA detected NABs in 15 of them, giving an overall specificity of 54.8% (AdipoGen) and 82% (NeutralISA) respectively.

Among vaccinated individuals both sELISA detected NABs in all 136 NT-positive samples resulting in a sensitivity and specificity of 100%. At the same time, of the 114 NT-positive samples from convalescent patients, the AdipoGen identified 109 samples as positive (95.6% sensitivity) while the NeutralISA detected 79 positive samples (69.3% sensitivity). In addition,

of the 14 NT-negative samples from convalescent patients the AdipoGen identified more than half (n=8) as positive (42.9% specificity) while NeutralISA detected no NABs in all 14 samples (100% specificity). Of the 30 negative control samples all were identified as negative by both sELISA resulting in 100% specificity each.

With regard to both LFA tested, sensitivity and specificity also varied between tests. The Concile identified all but four NT positive samples resulting in the highest overall sensitivity (98.4%) of all four tests evaluated. At the same time, the Coris identified significantly less NT positive samples, resulting in an overall sensitivity of 71.6%. Similar results were obtained among samples from convalescent and fully vaccinated individuals with the Concile showing continuously high sensitivities (97.4% - 99.3%). In contrast, the Coris showed the lowest sensitivities among all four tests (65.8% - 76.5%). Overall, all tests achieved their highest sensitivity with samples from fully vaccinated individuals while sensitivities were lowest when testing samples from convalescent patients. In terms of specificity, the Concile identified 35 of 84 negative samples as positive resulting in an overall specificity of 58.3%. Similar results were obtained among samples from convalescent (42.9%) and partially vaccinated (32.5%) individuals. In contrast, a specificity of 100% was achieved when testing negative control samples. At the same time, of the 84 negative samples the Coris identified all but nine samples as negative, giving an overall specificity of 89.3%. Similar results were obtained for samples from convalescent patients (85.7%), partially vaccinated individuals (82.5%) and control samples (100%).

The percentage of positive results of all four tests in relation to the results obtained by NT is shown in figure 4. While both the Coris (light green) and the NeutralISA (light blue) have moderately low levels of false positive test results for NT-negative samples (i.e. 10.7% and 17.8%), the Concile and AdipoGen both have similarly high numbers of false positive among NT-negative samples (i.e. 41.7% and 45.2%). However, when looking at NT-positive samples, the Concile and AdipoGen have consistently good detection rates of $\geq 94\%$ among all titer levels. Detection rates of the NeutralISA improve with rising NT titers and reach 100% for samples with a titer ≥ 40 along with the Concile and the AdipoGen. Detection rates of the Coris also gradually improve with rising titers but remain overall low compared to the other three tests (the only exception being samples with a titer of ≥ 80).




Figure 4: Plot of the percentage of positive results of all four tests in comparison to the respective NT titer




Figure 5: Distribution of antibody quantities ($\mu\text{g/ml}$) determined by the Concile InfectCheck COVID-19 Nab in relation to the results of the NT In accordance with the manufacturer's instructions, cut-off was set to $0.3 \mu\text{g/ml}$. Despite a wide distribution of results (R^2 0.3, $p < 0.0001$), a low-grade linear trend could be observed with the highest precision observed for samples with high NT-titers (≥ 80).

The correlation between all four immunoassays as well as the correlation of each assay with the NT are shown in Table 3. Correlations were mostly medium to strong with the only exception of the Coris NP assay. The closest correlation (0.96) was observed between both sELISA followed by the NeutraLISA and the Concile (0.9). A medium correlation (0.8 – 0.85)

was demonstrated between all assays and the NT with the NeutralISA exhibiting the closest correlation to the NT. In general, the Coris exhibited the weakest correlations with all other assays including the weakest correlation (0.67) that was observed between the Coris and the AdipoGen. As expected, no correlations at all were observed between the Coris specifically targeted at NP-specific antibodies and all other (spike protein specific) assays.

	NT	AdipoGen	NeutralISA	Coris (NP)	Coris	Concile
NT	1,00	0,84	0,85	0,13	0,80	0,84
AdipoGen		1,00	0,96	-0,17	0,67	0,83
NeutralISA			1,00	-0,12	0,73	0,90
Coris (NP)				1,00	0,19	0,13
Coris					1,00	0,76
Concile						1,00

Table 3: Correlation between all immunoassays and with NT All coefficients are significant ($p < 0.0001$) with the only exception of the Coris NP assay; correlations are marked in color; strong correlations are marked in green shades while weaker correlations are marked in yellow, orange and red.

As the Coris not only detects RBD specific antibodies, but also antibodies against the nucleocapsid protein (NP), we examined all samples from convalescent patients ($n=128$) with a previous PCR-confirmed infection specifically for antibodies against NP. NP specific antibodies were detected in a little over half of the samples ($83/128$) resulting in a NP specific sensitivity of 65%. At the same time, we also tested the 30 negative control samples, of which all were NP negative, giving a specificity of 100%. We did not include the samples from partially/fully vaccinated individuals as our information is not sufficient to exclude a past SARS-CoV-2 infection with absolute certainty.

Discussion

Infection with SARS-CoV-2 elicits a humoral immune response that results in antibodies against specific viral proteins, including neutralizing antibodies (NAb). In this study, we

investigated four immunassays, i.e. two surrogate ELISA (sELISA) and two lateral flow assays (LFA), specifically designed for the detection of SARS-CoV-2 NABs and evaluated their sensitivity and specificity in direct comparison to a gold standard virus based method (NT).

Of the 334 serum samples evaluated in this study, the majority came from convalescent patients (38%) and fully vaccinated individuals (41%). Interestingly, mean NT titers differed markedly between convalescent and vaccinated individuals, with titers nearly four times higher in the latter. In addition, we were able to detect NAb in all samples from vaccinated individuals while 11% of samples from convalescent patients were negative for NAb. This is also in line with a recent study by Cavanaugh et al. who found that a full vaccination provides significantly better protection against reinfection compared to natural infection [13]. Remarkably, no NAb at all could be detected in partially vaccinated individuals. This observation was somewhat surprising because it contrasts with other studies in which at least low levels of neutralizing antibodies were detected after primary vaccination [14,15]. Since the samples were collected at similar time points after vaccination, this discrepancy is likely due to differences in testing methods. Our NT was essentially designed as a PRNT100 to maximize specificity and detect actual protective neutralizing antibodies with the highest possible confidence. However, this approach implies a reduction in test sensitivity and may explain the differences with studies using other methods such as PRNT50 or surrogate ELISA tests. This explanation is also supported by our finding that, although the NT results were negative, both sELISA and both LFA tested in this study detected NAb in many samples from partially vaccinated individuals.

The highest overall sensitivity (98.4%) was observed for the Concile despite it being a LFA, closely followed by the AdipoGen sELISA (98%). In contrast, sensitivity was lower for the NeutralISA sELISA (86%) while the Coris exhibited the least sensitivity (71.6%). But while the NeutralISA demonstrated a similar overall specificity of 82.1%, the AdipoGen and Concile both exhibited a markedly lower overall specificity (54.8% and 58.3% respectively). In contrast, the Coris was the only test with a specificity (89.3%) higher than the sensitivity. Sensitivity of all four tests was highest when testing samples of fully vaccinated individuals. The fact that the Coris LFA offers the simultaneous detection of NP specific antibodies is potentially interesting. However, the NP specific sensitivity of only 65% is not sufficient to reliably confirm or exclude a previous infection. The low specificity of the Concile and the AdipoGen is due to a large number of apparent false positive results within the groups of partially vaccinated and

convalescent individuals. In this context, we observed strikingly different specificities when testing different subgroups. Most interestingly, all four tests exhibited a specificity of 100% in the group of negative control samples, i.e. samples taken prior to the appearance of SARS-CoV-2. This is in stark contrast to the specificities determined based on testing samples from partially vaccinated individuals, which were as low as 25%. Similar results were observed for NT-negative samples from convalescent individuals, raising the question if these samples are truly negative. As already mentioned above, this discrepancy could be due to the fact that our NT is very conservatively designed to be as specific as possible. This limitation might lead to an underestimation of specificity of the evaluated test. In this context, the observation that samples after prime immunization have detectable but generally low antibody levels [15–17] is consistent. At the same time, another possible explanation for this discrepancy could be the presence of SARS-CoV-2 specific antibodies without neutralizing activity. Such non-neutralizing antibodies may cross-react with both sELISA and LFA and lead to false positive results due to their artificial nature. In addition, we observed only very little correlation (R^2 0.26, $p < 0.0001$) between the entirety of IgG antibodies and NAb, including high levels of antibodies but no neutralizing activity which could favor cross-reactivity.

Currently, there is a global effort to promote SARS-CoV-2 immunization. However, many countries have recently reported stagnating numbers of vaccinations. At the same time, countries are trying to return to normality and gradually ease restrictions, mostly for fully vaccinated people, while at the same time reports have begun to emerge about suboptimal immune responses after vaccination, especially among risk groups [18–20]. Albeit still missing data on correlate of protection [21], this has led to an increased demand for NAb testing to assess vaccination success. In addition, recent publications have indicated a beneficial effect of booster vaccinations to mitigate the reported decline in NAb [22–25], which has further increased the demand for NAb testing to select eligible groups.

Based on the results of this study, both sELISA are suitable to be used as alternative testing methods in determining NAb levels post immunization (and with minor compromises also post infection) when NT testing is not available in standard laboratories. A huge advantage of both sELISA is, of course, the significantly reduced turn-around time of only a few hours compared to several days. The same can be said about the Concile LFA, which can be used by medical practices and other non-laboratory institutions due to its quick and easy workflow and turn-around of only 20 minutes.

Contributions:

PG: Conceptualization, Methodology, Visualization, Writing – review & editing; **KZ:** Conceptualization, Methodology, Visualization, Writing – review & editing; **HvB:** Data curation, Writing – review & editing; **RW:** Data curation, Writing – review & editing; **KM:** Conceptualization, Methodology, Writing – original draft, Visualization.

References

- [1] Gudina EK, Ali S, Girma E, Gize A, Tegene B, Hundie GB, et al. Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities. *The Lancet Global Health* 2021;9:e1517–27. [https://doi.org/10.1016/S2214-109X\(21\)00386-7](https://doi.org/10.1016/S2214-109X(21)00386-7).
- [2] Aziz NA, Corman VM, Echterhoff AKC, Müller MA, Richter A, Schmandke A, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. *Nature Communications* 2021;12:2117. <https://doi.org/10.1038/s41467-021-22351-5>.
- [3] Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature Medicine* 2021:1–7. <https://doi.org/10.1038/s41591-021-01377-8>.
- [4] Barnes CO, Jette CA, Abernathy ME, Dam K-MA, Esswein SR, Gristick HB, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature* 2020;588:682–7. <https://doi.org/10.1038/s41586-020-2852-1>.
- [5] Piccoli L, Park Y-J, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* 2020;183:1024-1042.e21. <https://doi.org/10.1016/j.cell.2020.09.037>.
- [6] Khoury DS, Wheatley AK, Ramuta MD, Reynaldi A, Cromer D, Subbarao K, et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. *Nat Rev Immunol* 2020;20:727–38. <https://doi.org/10.1038/s41577-020-00471-1>.
- [7] GeurtsvanKessel CH, Okba NMA, Igloi Z, Embregts CWE, Laksono BM, Leijten L, et al. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment. *MedRxiv* 2020:2020.04.23.20077156. <https://doi.org/10.1101/2020.04.23.20077156>.
- [8] Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. *Emerging Microbes & Infections* 2020;9:680–6. <https://doi.org/10.1080/22221751.2020.1743767>.
- [9] Yang R, Huang B, Ruhan A, Li W, Wang W, Deng Y, et al. Development and effectiveness of Pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro. *Biosafety and Health* 2020. <https://doi.org/10.1016/j.bsheal.2020.08.004>.
- [10] Kohmer N, Rühl C, Ciesek S, Rabenau HF. Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies. *J Clin Med* 2021;10. <https://doi.org/10.3390/jcm10102128>.
- [11] Valdivia A, Torres I, Latorre V, Francés-Gómez C, Ferrer J, Forqué L, et al. Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS-CoV-2 neutralizing activity of sera. *J Med Virol* 2020. <https://doi.org/10.1002/jmv.26697>.

- [12] Haselmann V, Özçürümez MK, Klawonn F, Ast V, Gerhards C, Eichner R, et al. Results of the first pilot external quality assessment (EQA) scheme for anti-SARS-CoV-2-antibody testing. *Clin Chem Lab Med* 2020. <https://doi.org/10.1515/cclm-2020-1183>.
- [13] Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination - Kentucky, May-June 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1081–3. <https://doi.org/10.15585/mmwr.mm7032e1>.
- [14] Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *The Lancet* 2021;397:2331–3. [https://doi.org/10.1016/S0140-6736\(21\)01290-3](https://doi.org/10.1016/S0140-6736(21)01290-3).
- [15] Bradley T, Grundberg E, Selvarangan R, LeMaster C, Fraley E, Banerjee D, et al. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine. *New England Journal of Medicine* 2021;384:1959–61. <https://doi.org/10.1056/NEJMc2102051>.
- [16] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine* 2020;383:2603–15. <https://doi.org/10.1056/NEJMoa2034577>.
- [17] Jeewandara C, Kamaladasa A, Pushpakumara PD, Jayathilaka D, Aberathna IS, Danasekara DRSR, et al. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. *Nature Communications* 2021;12:4617. <https://doi.org/10.1038/s41467-021-24579-7>.
- [18] Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. *MedRxiv* 2021:2021.04.06.21254949. <https://doi.org/10.1101/2021.04.06.21254949>.
- [19] Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. *Nat Med* 2021:1–10. <https://doi.org/10.1038/s41591-021-01542-z>.
- [20] Lippi G, Henry BM, Plebani M. Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How? *Diagnostics* 2021;11:941. <https://doi.org/10.3390/diagnostics11060941>.
- [21] Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nat Med* 2021;27:1147–8. <https://doi.org/10.1038/s41591-021-01432-4>.
- [22] Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *N Engl J Med* 2021;385:1393–400. <https://doi.org/10.1056/NEJMoa2114255>.
- [23] Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al. Considerations in boosting COVID-19 vaccine immune responses. *The Lancet* 2021;398:1377–80. [https://doi.org/10.1016/S0140-6736\(21\)02046-8](https://doi.org/10.1016/S0140-6736(21)02046-8).
- [24] Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. BNT162b2 vaccine booster dose protection: A nationwide study from Israel. *MedRxiv* 2021:2021.08.27.21262679. <https://doi.org/10.1101/2021.08.27.21262679>.
- [25] Yue L, Xie T, Yang T, Zhou J, Chen H, Zhu H, et al. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine. *Journal of Medical Virology* n.d.;n/a. <https://doi.org/10.1002/jmv.27334>.